ESALF News and Press, Eisai Co Ltd From 02/03/22

Eisai Co., Ltd. (ESALF) Q3 2022 Earnings Conference Call February 3, 2022, 2:00 AM ET Company Participants Dr. Ryohei Yanagi - Chief Financial Officer Ivan Cheung - President, Neurology Business Group Dr. Takashi Owa - President, Oncology Business Group Teruyuki Masaka - In-charge, Business P...

Eisai press release (OTCPK:ESALF): 9M  GAAP EPS of ¥210.50. Revenue of ¥565.3B (+13.4% Y/Y). For further details see: Eisai GAAP EPS of ¥210.50, revenue of ¥565.3B

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

Galapagos is in the midst of a transformation process that is expected to result in a completely different company by 2023. Galapagos has over $5.5 billion in cash, an approved drug and a broad pipeline with a market capitalization of only $3.2 billion. Jyseleca is approved in Jap...

Eisai Co., Ltd. (ESALF) Q2 2022 Earnings Conference Call November 1, 2021 03:00 AM ET Company Participants Haruo Naito - CEO Ivan Cheung - President, Neurology Conference Call Participants Hidemaru Yamaguchi - Citigroup Shinichiro Muraoka - Morgan Stanley Fumiyoshi Sakai - Crédit Suisse ...

The following slide deck was published by Eisai Co., Ltd. in conjunction with their 2022 Q2 earnings call. For further details see: Eisai Co., Ltd. 2022 Q2 - Results - Earnings Call Presentation

Eisai (OTCPK:ESALF): 1H GAAP EPS of ¥161.08. Revenue of ¥362.35B (+14.3% Y/Y) Press Release FY2021 guidance: Revenue of ¥730B; Profit for the year attributable to owners of the parent ¥60.5B and EPS per basic share of ¥211.00. For further de...

Radius Health (RDUS +15.2%) has recorded the biggest intraday gain since May to reach a three-month high after the company announced that its experimental therapy elacestrant met the primary endpoint in a late-stage trial for certain patients with breast cancer. Out-licensed to Menarini ...

Biogen (NASDAQ:BIIB) is scheduled to announce Q3 earnings results on Wednesday, October 20th, before market open. The consensus EPS Estimate is $4.11 (-53.5% Y/Y) and the consensus Revenue Estimate is $2.67B (-21.0% Y/Y). Over the last 2 years, BIIB has beaten EPS estimates 88% of the time an...

With a list of 62 recent IPOs making entry to The Russell 2000 small-cap index after index provider FTSE Russell implemented its Q3 recalibrations, we discuss the recently-IPOd healthcare stocks joining the index. Following up on our previous article on biotech stocks in the group, ...